Cargando…
A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus
The Gn subcomponent of the Gn-Gc assembly that envelopes the human and animal pathogen, Rift Valley fever virus (RVFV), is a primary target of the neutralizing antibody response. To better understand the molecular basis for immune recognition, we raised a class of neutralizing monoclonal antibodies...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315105/ https://www.ncbi.nlm.nih.gov/pubmed/30590046 http://dx.doi.org/10.1016/j.celrep.2018.12.001 |
_version_ | 1783384212028522496 |
---|---|
author | Allen, Elizabeth R. Krumm, Stefanie A. Raghwani, Jayna Halldorsson, Steinar Elliott, Angela Graham, Victoria A. Koudriakova, Elina Harlos, Karl Wright, Daniel Warimwe, George M. Brennan, Benjamin Huiskonen, Juha T. Dowall, Stuart D. Elliott, Richard M. Pybus, Oliver G. Burton, Dennis R. Hewson, Roger Doores, Katie J. Bowden, Thomas A. |
author_facet | Allen, Elizabeth R. Krumm, Stefanie A. Raghwani, Jayna Halldorsson, Steinar Elliott, Angela Graham, Victoria A. Koudriakova, Elina Harlos, Karl Wright, Daniel Warimwe, George M. Brennan, Benjamin Huiskonen, Juha T. Dowall, Stuart D. Elliott, Richard M. Pybus, Oliver G. Burton, Dennis R. Hewson, Roger Doores, Katie J. Bowden, Thomas A. |
author_sort | Allen, Elizabeth R. |
collection | PubMed |
description | The Gn subcomponent of the Gn-Gc assembly that envelopes the human and animal pathogen, Rift Valley fever virus (RVFV), is a primary target of the neutralizing antibody response. To better understand the molecular basis for immune recognition, we raised a class of neutralizing monoclonal antibodies (nAbs) against RVFV Gn, which exhibited protective efficacy in a mouse infection model. Structural characterization revealed that these nAbs were directed to the membrane-distal domain of RVFV Gn and likely prevented virus entry into a host cell by blocking fusogenic rearrangements of the Gn-Gc lattice. Genome sequence analysis confirmed that this region of the RVFV Gn-Gc assembly was under selective pressure and constituted a site of vulnerability on the virion surface. These data provide a blueprint for the rational design of immunotherapeutics and vaccines capable of preventing RVFV infection and a model for understanding Ab-mediated neutralization of bunyaviruses more generally. |
format | Online Article Text |
id | pubmed-6315105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Cell Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63151052019-01-08 A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus Allen, Elizabeth R. Krumm, Stefanie A. Raghwani, Jayna Halldorsson, Steinar Elliott, Angela Graham, Victoria A. Koudriakova, Elina Harlos, Karl Wright, Daniel Warimwe, George M. Brennan, Benjamin Huiskonen, Juha T. Dowall, Stuart D. Elliott, Richard M. Pybus, Oliver G. Burton, Dennis R. Hewson, Roger Doores, Katie J. Bowden, Thomas A. Cell Rep Article The Gn subcomponent of the Gn-Gc assembly that envelopes the human and animal pathogen, Rift Valley fever virus (RVFV), is a primary target of the neutralizing antibody response. To better understand the molecular basis for immune recognition, we raised a class of neutralizing monoclonal antibodies (nAbs) against RVFV Gn, which exhibited protective efficacy in a mouse infection model. Structural characterization revealed that these nAbs were directed to the membrane-distal domain of RVFV Gn and likely prevented virus entry into a host cell by blocking fusogenic rearrangements of the Gn-Gc lattice. Genome sequence analysis confirmed that this region of the RVFV Gn-Gc assembly was under selective pressure and constituted a site of vulnerability on the virion surface. These data provide a blueprint for the rational design of immunotherapeutics and vaccines capable of preventing RVFV infection and a model for understanding Ab-mediated neutralization of bunyaviruses more generally. Cell Press 2018-12-26 /pmc/articles/PMC6315105/ /pubmed/30590046 http://dx.doi.org/10.1016/j.celrep.2018.12.001 Text en © 2018 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Allen, Elizabeth R. Krumm, Stefanie A. Raghwani, Jayna Halldorsson, Steinar Elliott, Angela Graham, Victoria A. Koudriakova, Elina Harlos, Karl Wright, Daniel Warimwe, George M. Brennan, Benjamin Huiskonen, Juha T. Dowall, Stuart D. Elliott, Richard M. Pybus, Oliver G. Burton, Dennis R. Hewson, Roger Doores, Katie J. Bowden, Thomas A. A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus |
title | A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus |
title_full | A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus |
title_fullStr | A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus |
title_full_unstemmed | A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus |
title_short | A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus |
title_sort | protective monoclonal antibody targets a site of vulnerability on the surface of rift valley fever virus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315105/ https://www.ncbi.nlm.nih.gov/pubmed/30590046 http://dx.doi.org/10.1016/j.celrep.2018.12.001 |
work_keys_str_mv | AT allenelizabethr aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT krummstefaniea aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT raghwanijayna aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT halldorssonsteinar aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT elliottangela aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT grahamvictoriaa aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT koudriakovaelina aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT harloskarl aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT wrightdaniel aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT warimwegeorgem aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT brennanbenjamin aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT huiskonenjuhat aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT dowallstuartd aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT elliottrichardm aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT pybusoliverg aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT burtondennisr aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT hewsonroger aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT dooreskatiej aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT bowdenthomasa aprotectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT allenelizabethr protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT krummstefaniea protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT raghwanijayna protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT halldorssonsteinar protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT elliottangela protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT grahamvictoriaa protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT koudriakovaelina protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT harloskarl protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT wrightdaniel protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT warimwegeorgem protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT brennanbenjamin protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT huiskonenjuhat protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT dowallstuartd protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT elliottrichardm protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT pybusoliverg protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT burtondennisr protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT hewsonroger protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT dooreskatiej protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus AT bowdenthomasa protectivemonoclonalantibodytargetsasiteofvulnerabilityonthesurfaceofriftvalleyfevervirus |